In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Manguso RT, Pope HW, Zimmer MD, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413-418. doi:10.1038/nature23270 Read more